Cimoxatone
Chemical compound
- none
- 3-[[4-[5-(methoxymethyl)-2-oxo-oxazolidin-3-yl]phenoxy]methyl]benzonitrile
- 73815-11-9
Y
- 52542
- 47493
Y
- V6FT1QJ7VL
- D02581
Y
- ChEMBL2104092
N
- DTXSID50868273
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
InChI
- InChI=1S/C19H18N2O4/c1-23-13-18-11-21(19(22)25-18)16-5-7-17(8-6-16)24-12-15-4-2-3-14(9-15)10-20/h2-9,18H,11-13H2,1H3
Y
- Key:MVVJINIUPYKZHR-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Cimoxatone (MD 780515) is a reversible inhibitor of MAO-A (RIMA).[1] It has a significant food interaction–related adverse effect in combination with tyramine.[2] It was never marketed.
See also
- Monoamine oxidase inhibitor
References
- ^ Nair NP, Ahmed SK, Kin NM, West TE (1995). "Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients". Acta Psychiatr Scand Suppl. 386: 28–35. doi:10.1111/j.1600-0447.1995.tb05921.x. PMID 7717092. S2CID 9100689.
- ^ Nair NP, Ahmed SK, Kin NM (November 1993). "Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide". J Psychiatry Neurosci. 18 (5): 214–25. PMC 1188542. PMID 7905288.
- v
- t
- e
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e